ARTICLE
11 November 2019

Rammazini Institute, IARC Slammed On Transparency Issues

CC
Clyde & Co

Contributor

Clyde & Co  logo
Clyde & Co is a leading, sector-focused global law firm with 415 partners, 2200 legal professionals and 3800 staff in over 50 offices and associated offices on six continents. The firm specialises in the sectors that move, build and power our connected world and the insurance that underpins it, namely: transport, infrastructure, energy, trade & commodities and insurance. With a strong focus on developed and emerging markets, the firm is one of the fastest growing law firms in the world with ambitious plans for further growth.
Rammazini Institute and International Agency for Research on Cancer criticized for conflict of interest on glysophate research.
United Kingdom Food, Drugs, Healthcare, Life Sciences

Rammazini Institute and International Agency for Research on Cancer criticized for conflict of interest on glysophate research.

Parties in toxic tort litigation are no doubt familiar with the plaintiffs' bar using the "alphabet soup" of various administrative, quasi-governmental, and research agencies' positions on the toxicity and/or carcinogenicity of substances in order to advance their general and specific causation arguments at trial. This tactic has been highly effective for the plaintiffs' bar over the years given jurors' natural inclination to defer to such authority sources as above reproach and without conflicts of interest. Recently, the Collegium Ramazzini and IARC have received criticism on this front by way of a letter published in the journal Medicina Del Lavoro by five members of the University of Turin's School of Occupational Medicine.  The letter reveals that a member of the Ramazzini Institute who worked on the IARC monograph concerning glysophate (the chemical at issue in the many Roundup/cancer cases filed across the country, some of which have resulted in eight-figure plaintiffs' verdicts) did so while receiving compensation from a private law firm for work on glysophate litigation, which was a violation of the monograph program's rules. IARC's monograph on glysophate classified it as "probably carcinogenic" to humans.  The US EPA has since issued a decision stating that glysophate is not carcinogenic to humans. A copy of the letter can be found below.

Download here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More